Printer Friendly

Guidant Comments on the Status of its ACTION Drug Eluting Stent Trial.

Business Editors & Health/Medical Writers

INDIANAPOLIS--(BW HealthWire)--Feb. 22, 2002

Guidant Corporation (NYSE:GDT)(PCX:GDT), a global leader in cardiac and vascular technology, today issued the following statement on the status of its international ACTION clinical trial evaluating its drug eluting stent system utilizing Actinomycin D. The company is issuing this statement in response to speculation on the trial based on anecdotal data.

Guidant is now in the six-month follow-up phase of the ACTION trial, having completed enrollment in November. Thirty-day follow-up has revealed no safety concerns. The results of the trial are blinded and the data is currently being collected for evaluation. Consequently, the company will not comment on anecdotal data or speculation relating to the trial.

Guidant is looking forward to its first opportunity to report on the full 360 patient ACTION data set at the Paris Course (cardiology medical conference) in late May.

The ACTION Trial is evaluating Guidant's internal drug eluting stent program utilizing Actinomycin-D in patients with de novo lesions in native coronary arteries. The trial enrolled the 360 patients at 28 centers primarily in Europe.

Guidant is advancing multiple drug eluting stent programs and is well on its way toward providing customers with the broadest and deepest drug eluting stent product line in the industry, the company stated.

Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to 7 million cardiac and vascular patients worldwide. The company, driven by a strong entrepreneurial culture of 10,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions. For more information visit
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Feb 22, 2002
Previous Article:More Gold For The World Gold Council; Online Lifestyle Magazine Wins Gold Award - and International Recognition.
Next Article:JLG Transitions to New Manufacturing Model; Company Integrates Production of Telehandler and AWP Product Groups.

Related Articles
First Patients Treated With Guidant's Drug-Eluting Stent; Clinical Trial Will Be Basis for CE Mark Approval of MULTI-LINK TETRA-D Stent.
Guidant Completes Enrollment Of First Drug-Eluting Stent Trial Utilizing Actinomycin-D.
Guidant Announces Filing for European Approval to Market Drug Eluting Stent; ACHIEVE CE Mark Filing Represents Milestone in Guidant's Drug Eluting...
Guidant Completes Enrollment Of Paclitaxel Drug-Eluting Stent U.S. Trial; Clinical Trial Fully Enrolled In Less Than Four Months.
Guidant Halts Further Development on actinomycin-D Drug Eluting Stent Program; Company to Host Webcast/Conference Call Today.
Guidant Licenses Everolimus From Novartis for Drug Eluting Stents.
Guidant Reports First Quarter Record Sales and Earnings.
Clinsights, Inc. Launches The "Drug Eluting Stent Center" on TCTMD.
Guidant Initiates New International Paclitaxel Eluting Stent Trial; Largest Study to Date, DELIVER II Will Evaluate Clinical Benefit of ACHIEVE Stent...
Guidant Announces Excellent Preliminary Results of Paclitaxel Eluting Stent Trial; DELIVER and ELUTES Data Continue to Support Benefit of Paclitaxel...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters